Ariela Katz

Articles

Predictive Factors Found for Treatment With FCO in CLL

July 14th 2017

A mutation on the NOTCH1 gene was shown to be an independent predictive factor for the reduced efficacy of ofatumumab (Arzerra), a human monoclonal CD20 antibody, in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

"Trojan Horse" Tested in EGFR-Amplified Glioblastoma

July 6th 2017

Investigators are seeking to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide will improve the survival of patients with newly diagnosed glioblastoma multiforme with EGFR amplification.

Clinical Trials Are Essential in the Adjuvant Setting for High-Risk Melanoma

June 30th 2017

Anna C. Pavlick, DO, discusses adjuvant therapy for patients with high-risk melanoma.

Feasibility Results Support Launching Full Phase III PART Trial in Prostate Cancer

June 22nd 2017

Based on results of a feasibility study, researchers in the United Kingdom have decided to move forward with a full randomized controlled trial comparing partial prostate ablation with radical prostatectomy in patients with intermediate-risk prostate cancer.

Cross-Resistance to Docetaxel and Cabazitazel in CRPC Mediated by ABCB1 Gene

June 22nd 2017

Results of an investigation indicate that resistance to docetaxel and cabazitaxel (Jevtana) in patients with castration-resistant prostate cancer is mediated by a common mechanism, overexpression of the ABCB1 gene.

Split-Dose Gemcitabine and Cisplatin Shows Good Responses in Neoadjuvant MIBC

June 22nd 2017

Study results demonstrated that split-doses of gemcitabine and cisplatin as neoadjuvant chemotherapy for treating muscle-invasive bladder cancer has a good pathologic response with a high safety profile.

How Urology Clinics of North Texas Is Overcoming Payment Challenges

June 21st 2017

As manufacturers charge increasingly higher prices for new therapies and even well-established agents, payers have responded with pressure on practices to justify every cost, and Urology Clinics of North Texas, like many other independent practices, is caught in the middle.

Recent Patterns Indicate PSA Testing Halt in Decline

June 20th 2017

A recent nationally representative study published in JAMA Internal Medicine found that previously reported declines in prostate-specific antigen testing have not continued in recent years, and that approximately one-third of men age 50 years or older still receive routine PSA tests.

Two Late-Stage Trials Test Novel PI3K Inhibitor in Non-Hodgkin Lymphoma

June 16th 2017

Copanlisib (BAY 80-6946), a novel PI3K inhibitor, is being combined with standard rituximab-based regimens in patients with relapsed, indolent non-Hodgkin lymphoma.

Evolving Neoadjuvant and Adjuvant Therapeutic Approaches in RCC

June 16th 2017

Surgical resection, including cytoreductive nephrectomy, remains the standard of care for most patients with renal cell carcinoma, but many patients will have a recurrence, and could benefit from additional therapy.

No Mortality Difference Between Prostatectomy, Observation in 20-Year Study

June 14th 2017

Radical prostatectomy does not significantly reduce all-cause or prostate cancer mortality compared with observation through nearly 20 years, according to the results from the phase III PIVOT trial.

Dacomitinib Bests Gefitinib in EGFR-Mutant NSCLC

June 6th 2017

Dacomitinib, a second-generation EGFR inhibitor, reduced the risk of disease progression by more than 40% and resulted in an average 6.5-month improvement in response duration compared with gefitinib (Iressa) as a first-line treatment for patients with advanced, EGFR-mutant non–small cell lung cancer.

Testicular Cancer Survivors Face Health Risks From Low Testosterone

June 3rd 2017

Nearly 40% of testicular cancer survivors had low testosterone levels, leading to a greater likelihood of chronic health problem compared with survivors with normal testosterone levels, according to study findings released at the 2017 ASCO Annual Meeting.

Marine-Derived Drug Anchors Chemo Regimen in SCLC Trial

June 1st 2017

Lurbinectedin (PM01183 or PM1183), a transcription inhibitor that induces DNA double-strand breaks, is being combined with doxorubicin in a phase III trial for patients with recurrent small cell lung cancer in the hopes of providing a superior option to the current standard-of-care second-line chemotherapy.

Biotech Executive Offers Glimpse of Testing Future

May 27th 2017

Foundation Focus CDx BRCA, can detect both germline and somatic BRCA1/2 mutations in women with ovarian cancer who are candidates for the PARP inhibitor rucaparib (Rubraca).

Docetaxel Combined With Dexamethasone Shows PSA Response in Patients With CRPC

May 24th 2017

A recent phase II trial demonstrated that the combination of docetaxel-based chemotherapy and dexamethasone showed significantly high PSA responses compared with previous studies in patients with CRPC.

SouthWest Urology Uses Quality-Focused Integrated Care Mode

May 19th 2017

Michael Barkoukis, MD, and Tim Sidor, MD, started SouthWest Urology of Cleveland, OH, in 1982 from scratch with $100,000 in borrowed capital, a box of pens, and a copy machine.

Emerging BTK Inhibitor Tested in B-Cell Malignancies

May 18th 2017

BGB-3111, a second-generation BTK inhibitor, is being tested in patients with refractory B-cell lymphoid malignancies in an effort to determine whether the novel oral small molecule is a viable therapeutic option and to better understand its pharmacologic properties.

PARP Inhibitors Attract Growing Interest in Prostate Cancer

May 16th 2017

The genomic landscape of metastatic castration-resistant prostate cancer is becoming increasingly well defined, with new clinical data emerging to clarify and, in many cases, support the use of PARP inhibitors.

Burnout in Urologists Lower Than Prior Reports, But Remains Serious Issue

May 15th 2017

As part of the 2016 American Urological Association Census, investigators randomly assigned Maslach Burnout Inventory questions to determine how many urologists met the criteria for burnout.